While much of the world was sent into a panic by the sudden emergence of the Omicron variant of the coronavirus, Moderna Inc. weathered the shock pretty well. Indeed, its shares have gained more than 25% in value since the World Health Organization labeled the microbe a “variant of concern” and gave it a Greek-letter designation Friday. That includes a 12% gain Monday, the first full trading day since Thanksgiving, and a retrenchment of about 7% during Tuesday’s trading. The obvious reason for the gain is that as a manufacturer of one of the two leading COVID-19 vaccines, Moderna stands to make a tidy profit from the resurgent crisis. The company recorded about $10.7 billion in revenue and more than $7.3 billion in profit from its vaccine in the first nine months of this year, and expects $17 billion to $22 billion in sales from the product next year. To read the full story.